Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recherche translationnelle : médecine personnalisée, médecine de précision, thérapies ciblées : marketing ou science ?
Marquet P, Longeray PH, Barlesi F; les participants à la table ronde N°1 de Giens XXX :; Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C. Marquet P, et al. Among authors: chatelut e. Therapie. 2015 Jan-Feb;70(1):1-10. doi: 10.2515/therapie/2014230. Therapie. 2015. PMID: 27393393 French. No abstract available.
Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?
Marquet P, Longeray PH, Barlesi F; participants of round table N°1 of Giens XXX:; Ameye V, Augé P, Cazeneuve B, Chatelut E, Diaz I, Diviné M, Froguel P, Goni S, Gueyffier F, Hoog-Labouret N, Mourah S, Morin-Surroca M, Perche O, Perin-Dureau F, Pigeon M, Tisseau A, Verstuyft C. Marquet P, et al. Among authors: chatelut e. Therapie. 2015 Jan-Feb;70(1):1-19. doi: 10.2515/therapie/2014231. Epub 2015 Feb 16. Therapie. 2015. PMID: 25679189 English, French.
Niveau de preuve du suivi thérapeutique pharmacologique du cisplatine.
Hulin A, Royer B, Chatelut E, Le Guellec C; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Hulin A, et al. Among authors: chatelut e. Therapie. 2010 May-Jun;65(3):151-5. doi: 10.2515/therapie/2010022. Therapie. 2010. PMID: 27392980 French.
Niveau de preuve du suivi thérapeutique pharmacologique du carboplatine.
Hulin A, Chatelut E, Royer B, Le Guellec C; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Hulin A, et al. Among authors: chatelut e. Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021. Therapie. 2010. PMID: 27392981 French.
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Dalenc F, Iuliano L, Filleron T, Zerbinati C, Voisin M, Arellano C, Chatelut E, Marquet P, Samadi M, Roché H, Poirot M, Silvente-Poirot S. Dalenc F, et al. Among authors: chatelut e. J Steroid Biochem Mol Biol. 2017 May;169:210-218. doi: 10.1016/j.jsbmb.2016.06.010. Epub 2016 Jun 22. J Steroid Biochem Mol Biol. 2017. PMID: 27343991
[Level of evidence for therapeutic drug monitoring of cisplatin].
Hulin A, Royer B, Chatelut E, Le Guellec C; Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Hulin A, et al. Among authors: chatelut e. Therapie. 2010 May-Jun;65(3):151-5. doi: 10.2515/therapie/2010022. Epub 2010 Aug 11. Therapie. 2010. PMID: 20699064 Review. French.
[Level of evidence for therapeutic drug monitoring of carboplatin].
Hulin A, Chatelut E, Royer B, Le Guellec C; Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Hulin A, et al. Among authors: chatelut e. Therapie. 2010 May-Jun;65(3):157-62. doi: 10.2515/therapie/2010021. Epub 2010 Aug 11. Therapie. 2010. PMID: 20699065 Review. French.
Identification of non-adherence to adjuvant letrozole using a population pharmacokinetics approach in hormone receptor-positive breast cancer patients.
Puszkiel A, Dalenc F, Tafzi N, Marquet P, Debled M, Jacot W, Venat-Bouvet L, Ferrer C, Levasseur N, Paulon R, Dauba J, Evrard A, Mauriès V, Filleron T, Chatelut E, Thomas F, White-Koning M. Puszkiel A, et al. Among authors: chatelut e. Eur J Pharm Sci. 2024 Aug 1;199:106809. doi: 10.1016/j.ejps.2024.106809. Epub 2024 May 22. Eur J Pharm Sci. 2024. PMID: 38788907 Free article.
244 results